Insmed (INSM) said Wednesday that brensocatib, its investigational dipeptidyl peptidase-1 inhibitor for non-cystic fibrosis bronchiectasis, demonstrated consistent efficacy and safety across three prespecified subgroups in the phase 3 Aspen trial.

The subgroup analyses included adolescents, patients on macrolide therapy, and those with varying blood eosinophil levels.

The data showed brensocatib reduced pulmonary exacerbations, prolonged time to first exacerbation, and slowed lung function decline compared with placebo, with a safety profile consistent with the overall trial population, according to the company.

The results were presented at the American Thoracic Society 2025 International Conference held between May 18 and May 21 in San Francisco.